新生血管性年龄相关性黄斑变性抗VEGF治疗后视力预后不良的特征分析
基于Fight Retinal Blindness!注册研究,纳入2007至2012年间1760只治疗初治的新生血管性年龄相关性黄斑变性眼,其中856只完成5年随访。抗VEGF治疗5年时,22.9%的眼发生持续≥15字母视力丧失,10.8%发生持续≥30字母丧失。年龄>80岁、注射次数少、脉络膜新生血管活跃 visit 比例高与≥15字母丧失风险升高独立相关,基线视力≥70字母与≥30字母丧失风险降低相关。
要点
- 年龄>80岁、注射次数少、CNV活跃 visit 多与视力丧失风险升高独立相关。
- 基线视力≥70字母与持续≥30字母丧失风险降低相关。
核心结论
- 基线预测因素有助于更准确评估抗VEGF治疗的潜在获益。
研究设计与样本
- 观察性研究,数据来自Fight Retinal Blindness!注册研究。
- 纳入2007至2012年间开始抗VEGF治疗的初治新生血管性年龄相关性黄斑变性眼,共1760只,其中856只完成5年随访。
主要发现
- 5年时持续≥15字母视力丧失比例为22.9%(95%CI 20.7%-25.1%),持续≥30字母丧失比例为10.8%(95%CI 9.1%-12.5%)。
- 年龄>80岁较≤80岁者持续≥15字母丧失风险更高(OR 1.33,95%CI 1.05-1.69,P=0.02)。
- 注射次数每增加1次,持续≥15字母丧失风险降低(OR 0.97,95%CI 0.96-0.98,P=0.0005)。
- 脉络膜新生血管活跃 visit 处于上四分位较最低四分位者持续≥15字母丧失风险更高(OR 1.97,95%CI 1.39-2.79,P=0.0001)。
- 基线视力≥70字母与持续≥30字母丧失风险降低相关(OR 0.61,95%CI 0.38-0.98,P=0.04)。
关键数值与推荐
- 持续≥15字母视力丧失定义为较基线丧失≥15字母且至终点未恢复。
- 基线血管造影病灶标准与持续视力丧失无显著关联。
临床怎么用
- 对年龄>80岁、注射次数少、CNV活跃 visit 比例高的患者应加强监测和随访。
- 基线视力较好(≥70字母)者持续严重视力丧失风险较低,可据此评估预后。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the incidence, characteristics, and baseline predictors of poor visual outcomes in eyes with neovascular age-related macular degeneration (nAMD) receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents in daily clinical practice. DESIGN: Observational study. PARTICIPANTS: Treatment-naive eyes starting anti-VEGF therapy for nAMD between 2007 and 2012 tracked in the Fight Retinal Blindness! registry. Eyes had sustained ≥15 letters of loss from baseline without recovery of visual acuity (VA) at final end point. A subgroup analysis included eyes that sustained ≥30 letters of loss. Controls had not sustained ≥15 letters of loss. METHODS: Kaplan-Meier curves estimated time to first development of loss of ≥15 letters. Cox proportional hazards models evaluated predictors of loss of ≥15 letters. MAIN OUTCOME MEASURES: The proportion of eyes with sustained VA loss within 5 years, the time to development of sustained VA loss, and baseline predictors of sustained VA loss. RESULTS: There were 1760 eyes in total and 856 eyes that completed 5 years follow-up. The proportion of eyes with sustained VA loss of ≥15 letters at 5 years was 22.9% (95% confidence interval [CI], 20.7%-25.1%) and VA loss of ≥30 letters was 10.8% (95% CI, 9.1%-12.5%). Factors independently associated with higher incidence of sustained ≥15-letter loss included age >80 years (odds ratio [OR], 1.33 for patients >80 years vs. ≤80 years; 95% CI, 1.05-1.69; P = 0.02), fewer injections (OR, 0.97 per injection; 95% CI, 0.96-0.98; P = 0.0005), and more visits at which the choroidal neovascularization was graded as active (OR, 1.97 for eyes in upper quartile of active visits vs. eyes in lowest quartile of active visits; 95% CI, 1.39-2.79; P = 0.0001). Baseline VA ≥70 letters was associated with reduced risk of sustained ≥30-letter loss (OR, 0.61; 95% CI, 0.38-0.98; P = 0.04). Baseline angiographic lesion criteria were not significantly associated with sustained VA loss. CONCLUSIONS: Twenty-three percent of eyes with nAMD developed sustained VA loss of ≥15 letters over 5 years of anti-VEGF therapy. Baseline predictors of poor outcomes provide more accurate assessment of the potential benefit from anti-VEGF therapy.
引用
- Nguyen CL, Gillies MC, Nguyen V, et al. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents. Ophthalmology. 2018. PMID: 30529685. doi:10.1016/j.ophtha.2018.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。